Power3 Medical Continues Progress on NuroPro Blood Test for Neurodegenerative Disease Detection

Company Retains Biostatistician to Increase Sensitivity of Testing

THE WOODLANDS, Texas, Jan. 11, 2005 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, announces the completion of the latest stage of clinical validation on the NuroPro(tm), a Neurodegenerative disease blood test used as a diagnostic tool in the early stage assessment of ALS, Alzheimer's, Parkinson's, and other diseases.

The Company continues to build a database of disease specific samples and will now use biostatistical analyses to select the optimum panel of biomarkers from a group of 34 identified biomarkers, to provide the highest measure of sensitivity and specificity. The biostatistical analysis will further enhance the validity of the NuroPro(tm) as a blood test that aids in the diagnosis of ALS, Alzheimer's and Parkinson's diseases.

The test has been developed by Power3 Medical in collaboration with Stan Appel, M.D., Chief of Neurology Service at the Methodist Hospital and Professor of Neurology at Baylor College of Medicine. The study-to-date has involved analyzing 438 blood serum samples from normal individuals and patients that have Lou Gehrig's (ALS), Alzheimer's, Parkinson's and other neurological diseases. The current results continue to concur with previous positive results.

According to Steven B. Rash, Power3 Medical's Chief Executive Officer, "The Company intends to commercialize a generic neurodegenerative disease test as well as three disease specific tests. Power3 projects that the ALS test will be the first test to be introduced to the market. We intend to and are in the process of seeking a strategic partner to co-develop these diagnostic solutions. I continue to be pleased with the progress that has been made."

To assist Power3 in the use of biostatistical analysis and further validation of the NuroPro, Dr. Lemuel A. Moye, Professor of Biostatistics at the University of Texas Health Science Center School of Public Health in Houston has been retained as the Company's biostatistician. Dr. Moye has earned a national reputation in the execution of multinational clinical trials. His involvement in these studies is in-depth, beginning with the design of the experiment and moving forward through the execution of the trial and into the analysis phase. Dr. Moye's work has been published in the New England Journal of Medicine, and the European Heart Journal.

About Power3 Medical Products, Inc.

Power3 Medical Products, http://www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are ``forward-looking statements.'' The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.


Contact Data